Scholars@Duke
Cameron James Oswalt

Cameron James Oswalt

Assistant Professor of Medicine
Medicine, Medical Oncology
cameron.oswalt@duke.edu
Medicine, Box 3099, Durham, NC 27710
10 Duke Medicine Circle, Durham, NC 27710

Scholarly Works

Alirocumab plus cemiplimab in immuno-refractory metastatic NSCLC: A single-arm, multi-center, phase 2 study.

Conference Journal of Clinical Oncology · June 1, 2026 2619Background: Immunotherapy resistance remains a significant unmet clinical need for most non-small cell lung cancer (NSCLC) patients. PCSK9 was shown in preclinical models to mediate cancer immunotherapy resistance and may serve as a novel immuno-inhibi ... Full text Cite

Abstract 6740: Selective immune activation of antigen activated T cells with STK-012, an a/b IL-2 receptor biased partial agonist, with pembrolizumab and chemotherapy in 1L PD-L1 negative non-squamous NSCLC

Conference Cancer Research · April 3, 2026 AbstractBackground:STK-012 is a first-in-class α/β-IL-2R biased partial agonist that drives antitumor activity by selectively s ... Full text Cite

Grief Among Oncology Providers: Prevalence and Association with Burnout.

Journal article J Cancer Educ · December 2025 International research shows that oncology providers frequently experience grief and that grief is linked to burnout. Evidence on the prevalence of grief and its link to burnout is limited, especially in the United States (US). We investigated the prevalen ... Full text Link to item Cite

Reducing unnecessary blood cultures in oncology through algorithmic stewardship in a tertiary medical center.

Journal article Support Care Cancer · August 12, 2025 BACKGROUND: Unnecessary blood cultures (BCx) increase healthcare costs, BCx contamination, and antibiotic overuse, particularly in cancer patients. Recent shortages in BCx bottles have amplified the need for more judicious BCx practices, especially in high ... Full text Link to item Cite

Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives.

Journal article Cancers (Basel) · June 21, 2025 Historically, systemic therapy for resectable non-small cell lung cancer (NSCLC) has been associated with a modest impact on overall survival. The current treatment options for early-stage resectable NSCLC include neoadjuvant, adjuvant, and perioperative i ... Full text Link to item Cite

Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.

Conference Journal of Clinical Oncology · June 2025 TPS8118Background: The addition of immune checkpoint blockade to neoadjuvant and adjuvant therapy is now standard of care in ... Full text Cite

Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives.

Preprint · May 5, 2025 Historically, systemic therapy for resectable non-small cell lung cancer (NSCLC) has been associated with modest impact in overall survival. Current treatment options for early-stage resectable NSCLC include use of neoadjuvant, adjuvant, and periop ... Full text Cite

Abstract A097: Analyzing immunotherapy resistance in microsatellite instable colorectal FFPE samples using RNA sequencing

Conference Cancer Immunology Research · February 23, 2025 AbstractINTRODUCTION: Immunotherapy outcomes have been underwhelming in most gastrointestinal malignancies. Microsatellite instable (MSI-H) colorectal cancers (CRC) are an exception. Immune checkpoint blocka ... Full text Cite

Timing of Palliative Care Consultation Impacts End of Life Care Outcomes in Metastatic Non-Small Cell Lung Cancer.

Journal article J Pain Symptom Manage · October 2024 CONTEXT: Early specialist palliative care (PC) involvement in metastatic non-small cell lung cancer (mNSCLC) is associated with improved quality of life, less aggressive end of life (EoL) care, and longer survival. As treatment paradigms for NSCLC have evo ... Full text Link to item Cite

Bone Marrow Failure due to Aplastic Anemia, Associated With Serous Fat Atrophy, and Treated With Allogeneic, Haploidentical Stem Cell Transplantation: A Case Report.

Journal article Case Rep Hematol · 2024 We describe the case of a 27-year-old male, previously healthy though with a social history notable for recreational cocaine use, who developed bone marrow failure due to aplastic anemia (AA) with associated serous fat atrophy (SFA). After the SFA was corr ... Full text Link to item Cite

The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps.

Journal article Curr Opin Oncol · July 1, 2023 PURPOSE OF REVIEW: While chemotherapy treatment options for patients with solid and hematologic malignancies have dramatically improved over recent years, chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) remain major barriers to deliveri ... Full text Link to item Cite

Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer.

Journal article J Cachexia Sarcopenia Muscle · December 2022 BACKGROUND: Weight loss (WL) has been associated with shorter survival in patients with advanced cancer, while obesity has been associated with longer survival. Integrating body mass index (BMI) and WL provides a powerful prognostic tool but has not been w ... Full text Open Access Link to item Cite

Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events.

Journal article J Immunother · July 2022 The mechanisms underlying tumor immunosurveillance and their association with the immune-related adverse events (irAEs) associated with checkpoint inhibitor immunotherapies remain poorly understood. We describe a metastatic melanoma patient exhibiting mult ... Full text Open Access Link to item Cite

Patient Advocacy During the Pandemic.

Journal article Acad Med · August 1, 2021 Full text Link to item Cite

Heart rate is an independent predictor of all-cause mortality in individuals with type 2 diabetes: The diabetes heart study.

Journal article World J Diabetes · January 15, 2018 AIM: To assess the association of resting heart rate with all-cause and cardiovascular disease (CVD) mortality in the Diabetes Heart Study (DHS). METHODS: Out of a total of 1443 participants recruited into the DHS, 1315 participants with type 2 diabetes wh ... Full text Link to item Cite